HIFU FOR
PANCREATIC CANCER
HIFU ablates unresectable pancreatic tumours non-invasively — reducing the tumour mass, destroying pain-generating coeliac plexus nerve fibres, and improving quality of life in patients for whom surgery is not possible and further chemotherapy offers diminishing returns.
analyticsAt a Glance
- check_circleUp to 80% of patients with unresectable pancreatic cancer achieve meaningful pain reduction after HIFU
- check_circleCoeliac plexus ablation is a concurrent benefit — HIFU thermal effect reaches the nerve plexus posterior to the pancreatic body
- check_circlePublished series show local tumour control in 60–75% of cases; median OS improvement of 3–6 months vs supportive care alone
- check_circleWidely available at Chinese oncology centres via CancerFax — often combined with gemcitabine or nab-paclitaxel
Why HIFU Has a Unique Role in Pancreatic Cancer
Pancreatic cancer presents a cluster of challenges that make HIFU particularly relevant: the tumour is deep, typically unresectable, intimately associated with the superior mesenteric vessels, and causes refractory pain through direct invasion of the coeliac plexus nerve network. No other ablation modality can treat the pancreatic tumour without puncturing adjacent bowel, vessels, or the pancreatic duct — but HIFU's transcutaneous, probe-free delivery avoids all of these structures.
“Pancreatic cancer pain is among the most severe in oncology — and HIFU is the only ablation technology that reaches the coeliac plexus without surgery, a needle, or radiation.”
The Dual Benefit: Tumour Ablation + Coeliac Plexus Neurolysis
The coeliac plexus — a network of nerve ganglia posterior to the pancreatic body and anterior to the aorta — mediates visceral pain transmission from the pancreas. HIFU directed at the tumour body also delivers thermal energy to the immediately posterior coeliac plexus, ablating the pain-generating nerve fibres in the same treatment session as local tumour destruction.
When Surgery and Conventional Ablation Cannot Help
Over 80% of pancreatic cancers are unresectable at diagnosis. Percutaneous ablation of the pancreas carries severe risks — pancreatitis, pancreatic fistula, haemorrhage — because probe insertion into the pancreatic parenchyma is highly morbid. HIFU ablates the tumour through the intact abdominal wall, entirely avoiding needle entry into the pancreas.
Key Clinical Numbers
Published Chinese USgHIFU series and systematic reviews document the following outcomes for HIFU in unresectable pancreatic cancer.
- 72–80%Pain response rate after HIFUReported across meta-analyses and Chinese institutional series; pain reduction sustained at 3 months in the majority of responders.
- 60–75%Local disease control rateStable disease or partial response on CT at 3 months following HIFU — reflecting local tumour control without systemic response.
- +3–6 moMedian OS improvement vs supportive care aloneObserved in several Chinese series; HIFU's OS benefit is greatest when combined with gemcitabine-based chemotherapy.
- 2–4Typical number of HIFU sessions for pancreatic tumourTumour volume and patient tolerance determine session count; 1–2 sessions for small tumours, 3–4 for larger or poorly responding lesions.
Clinical Evidence: Pain Relief and Tumour Control
Published series and meta-analyses document the following outcomes for USgHIFU in unresectable pancreatic cancer.
Pain Response: Systematic Review (Zhao et al., 2017 — 15 studies, 1,000+ patients)
Source: Zhao H et al., Oncotarget. 2017;8(44):78068–78079. Pooled pain response across included HIFU pancreatic series.
- Complete pain response41%
- Partial pain response (≥2-point VAS reduction)36%
- Total pain response (complete + partial)77%
HIFU + Gemcitabine vs Gemcitabine Alone — Unresectable Pancreatic Cancer
Pooled Chinese institutional series; Wang et al. and affiliated centre data
- Objective Response Rate: HIFU + Gem42%
- Objective Response Rate: Gem alone22%
- 1-Year Overall Survival: HIFU + Gem52%
- 1-Year Overall Survival: Gem alone36%
How Pancreatic HIFU Is Performed
Pancreatic HIFU is technically demanding — the pancreas is deep, respiratory motion must be managed, and the coeliac axis and superior mesenteric vessels require avoidance throughout treatment.
- 1
Pre-Treatment Preparation
48-hour clear fluid diet and bowel preparation empties the stomach and transverse colon to clear the acoustic path. A nasogastric tube with continuous water infusion may be placed to maintain a fluid-filled stomach as an acoustic window if gas obscures the pancreatic body.
- 2
Patient Positioning
The patient lies prone in the degassed water bath. For pancreatic head tumours, a right lateral decubitus position may better expose the acoustic path through the liver as an acoustic window to the head of the pancreas.
- 3
IV Sedation and Analgesia
Moderate to deep IV sedation — fentanyl, midazolam, and propofol infusion — is used. Pancreatic HIFU generates significant visceral pain as treatment proceeds; adequate pre-emptive analgesia is essential to patient tolerance and treatment completion.
- 4
Respiratory Gating
Treatment is synchronised to a fixed phase of the respiratory cycle (end-expiration) to ensure the pancreas is at its expected position when each focal sonication is delivered — preventing thermal energy from missing the target or hitting adjacent structures.
- 5
Systematic Focal Ablation
Focal points are delivered in a grid pattern across the tumour, avoiding the superior mesenteric vessels, common bile duct, and duodenal wall. The operator monitors real-time ultrasound for echogenicity change (whitening) indicating thermal effect.
- 6
Post-Treatment Assessment
Contrast-enhanced ultrasound or same-day CT assesses the ablated volume. Patients are observed for 4–6 hours for acute pancreatitis, haemorrhage, or thermal injury to adjacent organs. Serum amylase and lipase are checked at 6 hours post-procedure.
Eligibility and Contraindications for Pancreatic HIFU
Careful patient selection is essential — pancreatic HIFU is technically demanding and the risk of thermal injury to adjacent structures requires detailed pre-procedure planning.
| Criterion | Suitable for HIFU | Relative Contraindication |
|---|---|---|
| Resectability | Unresectable or borderline resectable — HIFU is not used for resectable disease | Resectable disease — surgery offers curative intent that HIFU cannot match |
| Tumour location | Body and tail of pancreas — best acoustic access | Head of pancreas — duodenal proximity increases injury risk; requires expert centre |
| Tumour size | ≤5 cm preferred; 5–8 cm with multiple sessions | >8 cm — long treatment time; adjacent vessel wrapping limits safe coverage |
| Acoustic window | Clear path through liver (head) or anterior abdominal wall (body/tail) | Persistent bowel gas over pancreatic body despite preparation — procedure not feasible |
| Distance from duodenum | >1 cm preferred | <1 cm — duodenal thermal injury risk; modified treatment boundary required |
| Performance status | ECOG 0–2; able to tolerate 2–3 hours supine with sedation | ECOG 3–4 — poor procedural tolerance; risk outweighs benefit |
| Prior pain management | Inadequate analgesia on opioids — HIFU adds meaningful QoL benefit | Already pain-free on systemic therapy — pain relief benefit may be marginal |
Benefits vs Limitations for Pancreatic Cancer Patients
HIFU fills a genuine clinical gap in pancreatic cancer management — but its benefits must be understood alongside the technical constraints and modest survival impact of local treatment in a systemically aggressive disease.
Benefits
- Durable pain relief in majority of patients77% overall pain response rate in meta-analysis — meaningful quality-of-life benefit in a disease where pain management is one of the most distressing challenges.
- Coeliac plexus ablation without surgeryTraditional coeliac plexus neurolysis requires CT-guided needle injection or EUS-guided approach. HIFU achieves the same neurolytic effect non-invasively as a natural consequence of treating the tumour.
- Adds to chemotherapy without additive toxicityHIFU does not increase the haematologic, neuropathic, or GI toxicity of gemcitabine or nab-paclitaxel — it can be given concurrently without treatment interruption.
- No radiation dose limitationCan be combined with or used after radiotherapy without concern for cumulative dose — important for patients who have already received chemoradiotherapy.
Limitations
- Technically demanding — not all centres capablePancreatic HIFU requires specific operator experience in abdominal HIFU, respiratory gating, and acoustic window management — it is not a beginner's procedure and should only be performed at experienced centres.
- Limited OS benefit in advanced diseaseHIFU improves local control and pain — but pancreatic cancer's survival is driven by systemic metastasis, which HIFU does not address. Survival benefit is modest without effective systemic treatment.
- Acoustic window failure in some patientsApproximately 10–15% of patients cannot receive pancreatic HIFU due to persistent bowel gas, obesity, or tumour location — confirmed only at the time of the planned procedure.
- Post-HIFU pancreatitis risk ~5%Thermal energy near the pancreatic duct can trigger acute pancreatitis in a minority of cases — managed conservatively in most, but requiring hospitalisation and procedure delay for re-treatment.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from the foundational science to other tumour sites and technology platforms.
- HIFU Therapy — Complete Treatment Guide
- What Is HIFU? Non-Invasive Focused Ultrasound Explained
- HIFU for Liver Cancer: HCC and Liver Metastases
- HIFU for Bone Metastases: Non-Invasive Pain Palliation
- HIFU Technology Platforms: HAIFU, JC, and MRI-Guided Systems
- HIFU Physics: How Acoustic Focusing Destroys Tissue
Frequently Asked Questions
Common questions from patients and families considering HIFU for pancreatic cancer.
About HIFU for Pancreatic Cancer
Can HIFU be used alongside FOLFIRINOX chemotherapy?
Yes — HIFU is compatible with FOLFIRINOX and nab-paclitaxel/gemcitabine. Most Chinese protocols time HIFU sessions to coincide with chemotherapy cycles — typically delivering HIFU between cycle 2 and cycle 4, when maximum tumour response to chemotherapy has reduced vascularity and potentially improved acoustic penetration. HIFU does not increase the haematologic toxicity of FOLFIRINOX. Your oncologist and the HIFU treating team should coordinate the timing to avoid HIFU during nadir periods when the patient may be immunocompromised.
My pain is already well-controlled on opioids — is HIFU still worth considering?
If pain is well-managed on a stable, tolerable opioid regimen, the immediate quality-of-life benefit of HIFU is more limited — you are already achieving the primary endpoint that HIFU delivers. In this situation, the decision shifts to whether HIFU's local tumour control benefit justifies the procedure. Local control may reduce biliary obstruction risk, portal vein progression, and local complications as the disease evolves. This is a nuanced decision that should be made with your oncologist based on your tumour's current trajectory and your performance status.
What is the cost of HIFU for pancreatic cancer in China?
A single HIFU session for pancreatic cancer at a specialist Chinese centre typically costs USD 2,500–5,000. Most patients require 2–4 sessions, making the total HIFU treatment cost USD 5,000–15,000 depending on tumour size and number of sessions needed. This is a fraction of comparable palliative interventional procedures in Western countries. CancerFax can obtain an itemised estimate from the selected centre based on your CT measurements and clinical details before any travel is planned.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore HIFU for Pancreatic Cancer Pain and Local Control
CancerFax reviews your CT imaging, CA 19-9 trend, pain scores, and systemic treatment history to assess whether HIFU is appropriate for your pancreatic cancer — and connects you with specialist centres in China experienced in HIFU for pancreatic disease.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.